

REMARKS

By the present amendment, applicants have corrected an obvious typographical error in Claim 29. The claims remaining for consideration by the Examiner are Claims 29, 31, 33-37, and 41-43.

The Examiner has rejected Claims 29, 31, 33-37 and 41-43 under 35 U.S.C. 102(e) as being anticipated by Reddy et al. (US 2004/0097568 A1).


As noted in this Office Action, the Examiner agrees that the priority documents have earlier filing dates than the reference, however, in order to claim benefit of the foreign priority documents, an English-language translation must be submitted with a certification of the accuracy of the translation.

In response, applicants have provided herewith English-language translations of the priority documents. Thus, the Reddy et al. (US 2004/0097568 A1) patent application may not be used as a reference.

It is respectfully submitted that applicants' claims are in condition for allowance and a notice of allowance is respectfully requested.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(609) 627-8507


John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Date: May 15, 2007